Cover Image
市場調查報告書

MRSA治療藥的全球市場:2016年∼2020年

Global MRSA Drugs Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 365951
出版日期 內容資訊 英文 79 Pages
訂單完成後即時交付
價格
Back to Top
MRSA治療藥的全球市場:2016年∼2020年 Global MRSA Drugs Market 2016-2020
出版日期: 2016年07月27日 內容資訊: 英文 79 Pages
簡介

MRSA是主要發生於醫院和醫療機關的皮膚感染疾病。一般使用抗生素治療,會由於皮膚和皮膚的直接接觸而擴大傳染。全球MRSA治療藥市場在2016年∼2020年這段期間,預測將以年複合成長率(CAGR)1.34%的速度成長。

本報告提供全球MRSA治療藥市場相關調查分析,提供您市場概要,各市場區隔考察,各地區考察,推動市場的要素,主要企業等概括性分析、彙整資料。

第1章 摘要整理

第2章 報告的範圍

第3章 市場調查的方法

  • 調查方法
  • 經濟指標

第4章 簡介

第5章 主要購買標準

第6章 抗菌:概要

  • 簡介
  • MOA
  • 使用抗生素的一般方針
  • 在臨床的利用

第7章 抗生素抗藥性

第8章 美國的抗生素使用相關法律

第9章 開發平台分析

第10章 市場的狀況

  • 全球抗菌藥市場
  • 全球MRSA市場
  • 波特的五力分析

第11章 MRSA治療藥的全球市場:各類藥物

第12章 MRSA治療藥的全球市場:各類型藥物

第13章 MRSA治療藥的全球市場:各MOA

第14章 MRSA治療藥的全球市場:各地區

  • 全球MRSA治療藥市場:各地區:2015年∼2020年
  • 南北美洲
  • 歐洲/中東/非洲
  • 亞太地區

第15章 MRSA治療藥的全球市場:促進要素

  • 法規的特別指定
  • 感染的增加
  • 疾病的關注度提升
  • 老年人口的增加

第16章 促進要素的影響

第17章 MRSA治療藥的全球市場:課題

第18章 促進要素與課題的影響

第19章 MRSA治療藥的全球市場:趨勢

  • 策略性同盟和M&A
  • 患者支援計劃
  • 抗生素研究的出資增加

第20章 供應商狀況

第21章 附錄

第22章 Technavio的其他的報告

目錄
Product Code: IRTNTR9071

About Methicillin-Resistant Staphylococcus aureus (MRSA)

MRSA is an infection of the skin that occurs mostly in hospitals and healthcare facilities. It is treated with commonly-used antibiotics and usually spreads from person to person by direct skin-to-skin contact. Physicians often find MRSA harder to treat than most other strains of Staphylococcus aureus because it is sometimes resistant to commonly-used antibiotics such as methicillin.

Technavio's analysts forecast the global MRSA drugs market to grow at a CAGR of 1.34% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global MRSA drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent MRSA infections.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global MRSA Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Allergan
  • Merck & Co.
  • Pfizer
  • Theravance Biopharma

Other Prominent Vendors

  • Absynth Biologics
  • AmpliPhi Biosciences Corporation
  • AstraZeneca
  • Basilea Pharmaceutica
  • Baxter International
  • Cellceutix
  • Cempra Inc.
  • CrystalGenomics
  • Debiopharm Group
  • Galapagos NV
  • GSK
  • KYORIN Pharmaceutical
  • Lytix Biopharma
  • Melinta Therapeutics
  • Nabriva Therapeutics
  • NovaDigm Therapeutics
  • Paratek Pharmaceuticals
  • R-Pharm
  • Savara Pharmaceuticals
  • Sealife Pharma
  • Sequella Inc.
  • The Medicines Company
  • XBiotech

Market driver

  • Special regulatory designations
  • For a full, detailed list, view our report

Market challenge

  • Development of drug-resistant strains
  • For a full, detailed list, view our report

Market trend

  • Strategic alliances and M&A
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Key buying criteria

PART 06: Antibacterial: Overview

  • Introduction
  • MOA
  • General principles for use of antibiotics
  • Clinical uses

PART 07: Antimicrobial resistance

  • Sources of spread of resistant organisms
  • Initiatives to improve antibiotic innovation
  • Surveillance systems for antibiotic resistance

PART 08: Legislation relating to antibiotics use in US

PART 09: Pipeline analysis

  • Solithromycin
  • TD-1792
  • Baxdela
  • Taksta

PART 10: Market landscape

  • Global antibacterial drugs market
  • Global MRSA drugs market
  • Five forces analysis

PART 11: Market segmentation by drug class

  • Tetracycline
  • Folate antagonists
  • Cephalosporin
  • Lipopeptide
  • Oxazolidinone
  • Lipoglycopeptide

PART 12: Market segmentation by drug origin

  • Semisynthetic drugs
  • Synthetic drugs

PART 13: Market segmentation by MOA

  • Bacteriostatic
  • Bactericidal

PART 14: Geographical segmentation

  • Global MRSA drugs market by geographical segmentation 2015-2020
  • MRSA drugs market in Americas
  • MRSA drugs market in EMEA
  • MRSA drugs market in APAC

PART 15: Market drivers

  • Special regulatory designations
  • Increasing prevalence of infections
  • Growing awareness of diseases
  • Rise in older population

PART 16: Impact of drivers

PART 17: Market challenges

  • Development of drug-resistant strains
  • Patent expiries and generic penetration
  • Decreased investments in research activities

PART 18: Impact of drivers and challenges

PART 19: Market trends

  • Strategic alliances and M&A
  • Patient assistance programs
  • Increased funding for antibiotic research

PART 20: Vendor landscape

  • Competitive scenario
  • Key vendor profiles
  • Allergan
  • Merck
  • Pfizer
  • Theravance
  • Other prominent vendors

PART 21: Appendix

  • List of abbreviations

PART 22: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Percentage of MRSA infections among Staphylococcus infections in US 2015
  • Exhibit 03: Percentage of MRSA infections in US based on type 2015
  • Exhibit 04: Sites of Staphylococcus infections
  • Exhibit 05: Key buying criteria for MRSA drugs
  • Exhibit 06: MOA of antibacterial drugs
  • Exhibit 07: General principles involved in use of antibiotics
  • Exhibit 08: Causes of AMR
  • Exhibit 09: Sources of spread of resistant organisms
  • Exhibit 10: Estimated deaths per year caused by AMR in 2050
  • Exhibit 11: Initiatives improving antibiotic innovation
  • Exhibit 12: Surveillance systems of various countries
  • Exhibit 13: Legislation relating to antibiotics use in US
  • Exhibit 14: Pipeline portfolio: Global MRSA drugs market
  • Exhibit 15: Global antibacterial drugs market 2015-2020 ($ billions)
  • Exhibit 16: Market share of global MRSA drugs in global pharmaceutical market 2015
  • Exhibit 17: Global MRSA drugs market 2015-2020 ($ billions)
  • Exhibit 18: Five forces analysis
  • Exhibit 19: Cephalosporin segmentation by generation of drugs
  • Exhibit 20: Global MRSA drugs market segmentation based on volume 2015
  • Exhibit 21: Global MRSA drugs market segmentation by drug origin
  • Exhibit 22: Global MRSA drugs market segmentation by geography 2015
  • Exhibit 23: Global MRSA drugs market revenue by geography 2015-2020 ($ millions)
  • Exhibit 24: Percentage share of global MRSA drugs market by geography 2015-2020
  • Exhibit 25: MRSA drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 26: Percentage share of MRSA drugs market in US 2015
  • Exhibit 27: MRSA drugs market in EMEA 2015-2020 ($ millions)
  • Exhibit 28: MRSA drugs market in APAC 2015-2020 ($ millions)
  • Exhibit 29: Global MRSA drugs market: YoY growth and revenue based on geography 2015-2020
  • Exhibit 30: Percentage of MRSA infections 2014
  • Exhibit 31: Impact of drivers
  • Exhibit 32: Antibiotic-resistant strains of Staphylococcus according to period of development of resistance
  • Exhibit 33: Ranking for top ten countries based on antibiotic consumption in livestock 2015
  • Exhibit 34: Antibacterial drug approvals by FDA and EMA
  • Exhibit 35: Impact of drivers and challenges
  • Exhibit 36: Allergan: Key takeaways
  • Exhibit 37: Merck: YoY revenue and growth rate of Cubicin 2013-2015 ($ billion)
  • Exhibit 38: Merck: Key takeaways
  • Exhibit 39: Pfizer: YoY revenue and growth rate of Zyvox 2013-2015 ($ millions)
  • Exhibit 40: Pfizer: YoY revenue and growth rate of Tygacil 2013-2015 ($ millions)
  • Exhibit 41: Pfizer: Key takeaways
  • Exhibit 42: Theravance Biopharma: YoY revenue comparison of Vibativ 2014-2015 ($ millions)
  • Exhibit 43: Theravance: Key takeaways
Back to Top